CSSN: ISSN 1000-467X CODEN: AIZHENG4 CN: 44-1195/R

CJC is published 12 times a year.

Sign up for Table of Contents Alerts!

home subscribe search archive forthcoming

Please note: CJC is published in English and Chinese. Manuscripts are published online prior to printing. The citation will change as volume, issue and page numbers are finalized.

Email this page Print this page

Clinical Research Paper

Expressions and Clinical Significance of a Disintegrin and Metalloprotease 8 (ADAM8) and Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer

Guo-Cheng Wu, Hua-Cheng Hu and Min-Hua Shi

volume 27 | issue 8

August 2008
Pages: 173 - 176

Purchase article for $19

Subscribe to this journal for $0/year

Background and Objective: Up-regulation of a disintegrin and metalloprotease 8 (ADAM8) is correlated with genesis, progression, invasion, and metastasis of tumors. However, the expression of ADAM8, especially its correlation to epidermal growth factor receptor (EGFR), has seldom been reported in non-small cell lung cancer (NSCLC). This study was to investigate expressions of ADAM8 and EGFR in NSCLC, and to analyze their correlations. Methods: Expressions of ADAM8 and EGFR in 49 specimens of NSCLC, 28 specimens of paracancerous lung tissues and 13 specimens of benign lung lesions were detected using tissue microarray (TMA) and immunohistochemmistry (IHC). The interrelationship between the two factors and their correlations to clinicopathologic features of NSCLC were analyzed. Results: ADAM8 and EGFR were mainly expressed in the cytoplasm and on the cell membrane. The positive rates of ADAM8 and EGFR were significantly higher in NSCLC than in paracancerous lung tissues and benign lung lesions (73.5% vs. 10.7% and 15.4%; 69.4% vs. 14.2% and 23.1%, p < 0.01). The positive rates of ADAM8 and EGFR were slightly lower in squamous cell carcinoma than in adenocarcinoma (73.1% vs. 80.0%; 65.4% vs. 75.0%, p > 0.05), while they were significantly higher in stage N1-N3 NSCLC than in stage N0 (85.7% vs. 42.8%; 82.8 vs. 35.7%, p < 0.01), and significantly higher in stage III-IV NSCLC than in stage I-II (90.0% vs. 62.1%; 90.0% vs. 65.5%, p < 0.05). The expression of ADAM8 was positively correlated to EGFR (r = 0.589, p < 0.01), with a kappa value of 0.522. Conclusion: ADAM8 and EGFR are overexpressed in NSCLC, and their expressions are consistent.

Authors

Guo-Cheng Wu

Soochow University

Hua-Cheng Hu

Soochow University

Min-Hua Shi

Soochow University


Purchase article for $19

Subscribe to this journal for $0/year